4.91

0.00% 0.00

Sage Therapeutics Inc (SAGE)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt SAGE? Forum Prognose

Schlusskurs vom Vortag:

$4.91

Offen:

$5.02

24-Stunden-Volumen:

804.08K

Relative Volume:

1.16

Marktkapitalisierung:

$304.64M

Einnahmen:

$91.06M

Nettoeinkommen (Verlust:

$-503.14M

KGV:

-0.495

EPS:

-9.92

Netto-Cashflow:

$-424.74M

1W Leistung:

-8.57%

1M Leistung:

-36.97%

6M Leistung:

-59.25%

1J Leistung:

-74.61%

1-Tages-Spanne:

$4.80

$5.19

1-Wochen-Bereich:

$4.62

$5.44

52-Wochen-Spanne:

$4.62

$28.26

Sage Therapeutics Inc Stock (SAGE) Company Profile

Firmenname

Sage Therapeutics Inc

Sektor

Healthcare (1195)

Branche

Biotechnology (683)

Telefon

617-299-8380

Adresse

55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA

Mitarbeiter

487

Twitter

@SageBiotech

Nächster Verdiensttermin

2024-10-29

Neueste SEC-Einreichungen

SAGE's Discussions on Twitter

Vergleichen Sie SAGE mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SAGE	4.91	304.64M	91.06M	-503.14M	-424.74M	-9.92
VRTX	449.69	115.43B	10.63B	-479.80M	-1.35B	13.33
REGN	748.75	82.04B	13.85B	4.65B	3.32B	35.06
ARGX	588.46	35.30B	1.86B	-40.29M	-1.28B	-4.16
ALNY	247.89	32.04B	2.09B	-332.26M	16.06M	-4.14
BNTX	106.23	24.89B	3.30B	-501.07M	1.03B	11.54

Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-12-12	Eingeleitet	Deutsche Bank	Hold
2023-08-08	Herabstufung	Canaccord Genuity	Buy → Hold
2023-08-08	Herabstufung	Goldman	Buy → Neutral
2023-08-08	Herabstufung	Needham	Buy → Hold
2023-08-07	Herabstufung	BofA Securities	Buy → Neutral
2023-08-07	Herabstufung	Oppenheimer	Outperform → Perform
2023-08-07	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2023-08-07	Herabstufung	Stifel	Buy → Hold
2023-08-07	Herabstufung	Wedbush	Outperform → Neutral
2023-07-27	Eingeleitet	Scotiabank	Sector Outperform
2023-03-13	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2023-01-03	Herabstufung	Guggenheim	Buy → Neutral
2022-11-01	Eingeleitet	Loop Capital	Hold
2022-03-31	Eingeleitet	Berenberg	Hold
2021-11-02	Hochstufung	Guggenheim	Neutral → Buy
2021-10-19	Fortgesetzt	Morgan Stanley	Equal-Weight
2021-10-07	Herabstufung	Jefferies	Buy → Hold
2021-09-23	Eingeleitet	Needham	Buy
2021-06-16	Herabstufung	Citigroup	Buy → Neutral
2021-04-07	Eingeleitet	Piper Sandler	Overweight
2021-02-26	Herabstufung	Mizuho	Buy → Neutral
2021-02-25	Bestätigt	H.C. Wainwright	Neutral
2021-02-02	Fortgesetzt	Raymond James	Mkt Perform
2021-01-22	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2021-01-04	Hochstufung	Guggenheim	Neutral → Buy
2021-01-04	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2020-12-04	Hochstufung	Mizuho	Neutral → Buy
2020-12-01	Herabstufung	Raymond James	Outperform → Mkt Perform
2020-11-16	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2020-11-06	Bestätigt	H.C. Wainwright	Neutral
2020-09-11	Hochstufung	Wedbush	Neutral → Outperform
2020-08-10	Hochstufung	Raymond James	Mkt Perform → Outperform
2020-05-08	Herabstufung	Wedbush	Outperform → Neutral
2020-04-08	Herabstufung	Guggenheim	Buy → Neutral
2020-03-18	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2020-03-06	Eingeleitet	Citigroup	Buy
2020-02-28	Bestätigt	H.C. Wainwright	Neutral
2020-02-06	Eingeleitet	Mizuho	Neutral
2019-12-06	Bestätigt	RBC Capital Mkts	Outperform
2019-12-05	Bestätigt	Guggenheim	Buy
2019-12-05	Herabstufung	SunTrust	Buy → Hold
2019-10-30	Eingeleitet	H.C. Wainwright	Neutral
2019-05-23	Eingeleitet	Wedbush	Outperform
2019-04-25	Eingeleitet	Jefferies	Buy
2018-12-14	Eingeleitet	Wolfe Research	Outperform
2018-10-11	Eingeleitet	Oppenheimer	Outperform

Alle ansehen

Sage Therapeutics Inc Aktie (SAGE) Neueste Nachrichten

12:13 PM

Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More - Yahoo Finance

12:13 PM

11:00 AM

Sage raised to sector perform by RBC in wake of drug failure - MSN

11:00 AM

07:41 AM

Sage scraps dalzanemdor after disappointing trial results - The Pharma Letter

07:41 AM

01:00 AM

Sage Therapeutics' Experimental Drug for Huntington's Disease Fails Mid-Stage Trial - Medical Dialogues

01:00 AM

12:43 PM

After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder - AOL

12:43 PM

Nov 20, 2024

Sage’s Pipeline Prospects Narrow Further As Dalzanemdor Fails In Huntington’s - Citeline News & Insights

Nov 20, 2024

Third trial failure is end-of-the-road for Sage's neurological drug - The Business Journals

Nov 20, 2024

Sage to abandon development of neurological disorder drug after multiple failures - Reuters

Nov 20, 2024

Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics - Benzinga

Nov 20, 2024

Sage Therapeutics (NASDAQ:SAGE) Earns Hold Rating from Needham & Company LLC - MarketBeat

Nov 20, 2024

Sage stock slips as Huntington’s Disease trial fails (SAGE:NASDAQ) - Seeking Alpha

Nov 20, 2024

Sage Therapeutics Shares Slide Premarket After Dalzanemdor Fails Again - MarketWatch

Nov 20, 2024

Sage Therapeutics scraps development of rare disease drug after it fails mid-stage study - XM

Nov 20, 2024

Sage Therapeutics’ stock slides after trial of Huntington’s Disease treatment fails and company says it will end it - MarketWatch

Nov 20, 2024

Sage Therapeutics' rare disease drug fails mid-stage study - XM

Nov 20, 2024

Sage Therapeutics Ends Huntington's Drug Development After Failed Phase 2 Trial | SAGE Stock News - StockTitan

Nov 20, 2024

Sage Therapeutics' stock falls after therapy fails for a third time - MarketWatch

Nov 20, 2024

Nov 19, 2024

CNS Drug Development: Same As It Ever Was (SAGE) - Seeking Alpha

Nov 19, 2024

Nov 18, 2024

Layoff Tracker: Gilead Sciences Will Lay Off 104 Employees at California HQ - BioSpace

Nov 18, 2024

Nov 16, 2024

SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GuruFocus.com

Nov 16, 2024

Nov 15, 2024

BB Biotech AG's Strategic Acquisition of Sage Therapeutics Shares - GuruFocus.com

Nov 15, 2024

Nov 13, 2024

FMR LLC Adjusts Stake in Sage Therapeutics Inc - GuruFocus.com

Nov 13, 2024

Nov 09, 2024

Easterly Investment Partners LLC Sells 91,500 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat

Nov 09, 2024

Nov 05, 2024

Sage Therapeutics' SWOT analysis: stock faces challenges amid CNS drug market shifts - Investing.com

Nov 05, 2024

Vanguard Group Inc's Recent Transaction in Sage Therapeutics Inc - GuruFocus.com

Nov 05, 2024

Nov 04, 2024

Objective long/short (SAGE) Report - Stock Traders Daily

Nov 04, 2024

Nov 02, 2024

Shareholders that lost money on Sage Therapeutics, Inc.(SAGE) sh - GuruFocus.com

Nov 02, 2024

Class Action Filed Against Sage Therapeutics, Inc. (SAGE) Seekin - GuruFocus.com

Nov 02, 2024

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on B - GuruFocus.com

Nov 02, 2024

Pinnacle Associates Ltd. Has $1.22 Million Stock Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat

Nov 02, 2024

Sage Therapeutics Inc Sued for Securities Law ViolationsConta - GuruFocus.com

Nov 02, 2024

Nov 01, 2024

Sage Therapeutics Reports Q3 Growth and Strategic Focus - TipRanks

Nov 01, 2024

Sage Prioritizes Zurzuvae For PPD, Ends MDD Effort, Drops Zulresso - Citeline News & Insights

Nov 01, 2024

SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit - GuruFocus.com

Nov 01, 2024

SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down - MSN

Nov 01, 2024

Sage Therapeutics CFO Kimi Iguchi resigns from position - XM

Nov 01, 2024

SAGE Therapeutics Announces Strategic Reorganization Amid Executive Departures - TipRanks

Nov 01, 2024

Cambridge biotech's layoffs will cut dozens of Mass. employees - The Business Journals

Nov 01, 2024

HC Wainwright Expects Weaker Earnings for Sage Therapeutics - MarketBeat

Nov 01, 2024

Oct 31, 2024

What is HC Wainwright's Estimate for SAGE FY2028 Earnings? - MarketBeat

Oct 31, 2024

Sage Therapeutics, Inc. (NASDAQ:SAGE) Q3 2024 Earnings Call Transcript - Insider Monkey

Oct 31, 2024

Sage Therapeutics price target lowered to $26 from $52 at Piper Sandler - Yahoo Finance

Oct 31, 2024

Oct 30, 2024